Business Description
NextCure Inc
NAICS : 325412
SIC : 2834
ISIN : US65343E1082
Description
Financial Strength
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 15.46 | |||||
Equity-to-Asset | 0.83 | |||||
Debt-to-Equity | 0.07 | |||||
Debt-to-EBITDA | -0.09 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -18.7 | |||||
3-Year EPS without NRI Growth Rate | -19.2 | |||||
3-Year FCF Growth Rate | -0.7 | |||||
3-Year Book Growth Rate | -27.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate | 23 |
Momentum Rank
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 53.42 | |||||
9-Day RSI | 44.14 | |||||
14-Day RSI | 41.71 | |||||
6-1 Month Momentum % | 6.82 | |||||
12-1 Month Momentum % | 13.8 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 8.35 | |||||
Quick Ratio | 8.35 | |||||
Cash Ratio | 7.98 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.4 | |||||
Shareholder Yield % | 1.54 |
Profitability Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -54.35 | |||||
ROA % | -47.94 | |||||
ROIC % | -417.97 | |||||
3-Year ROIIC % | 601.09 | |||||
ROC (Joel Greenblatt) % | -497.03 | |||||
ROCE % | -53.28 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.46 | |||||
Price-to-Tangible-Book | 0.46 | |||||
EV-to-EBIT | 0.64 | |||||
EV-to-EBITDA | 0.67 | |||||
EV-to-FCF | 0.9 | |||||
Price-to-Net-Current-Asset-Value | 0.54 | |||||
Price-to-Net-Cash | 0.57 | |||||
Earnings Yield (Greenblatt) % | 155.54 | |||||
FCF Yield % | -116.03 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
NextCure Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil €) | |||
EPS (TTM) (€) | -2.027 | ||
Beta | 0.45 | ||
Volatility % | 71.94 | ||
14-Day RSI | 41.71 | ||
14-Day ATR (€) | 0.028201 | ||
20-Day SMA (€) | 1.3012 | ||
12-1 Month Momentum % | 13.8 | ||
52-Week Range (€) | 0.96 - 2.275 | ||
Shares Outstanding (Mil) | 27.98 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 1 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
NextCure Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
NextCure Inc Stock Events
Event | Date | Price(€) | ||
---|---|---|---|---|
No Event Data |
NextCure Inc Frequently Asked Questions
What is NextCure Inc(FRA:2US)'s stock price today?
When is next earnings date of NextCure Inc(FRA:2US)?
Does NextCure Inc(FRA:2US) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |